D89.43 Código facturable y específico Secondary mast cell activation
ICD-10-CM D89.43 identifies “Secondary mast cell activation” as a billable/specific code in the FY2027 U.S. classification, effective October 1, 2026 through September 30, 2027.
Capítulo 3: Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism
Instrucciones del código
Inclusion terms1
Secondary mast cell activation syndrome
Code also1
underlying etiology, if known
Instrucciones de niveles superiores
Capítulos 3 · Diseases of the blood and blood-forming organs and certain disorders involving the immune mechanism (D50-D89)
Excludes 29
- autoimmune disease (systemic) NOS (M35.9)
- certain conditions originating in the perinatal period (P00-P96)
- complications of pregnancy, childbirth and the puerperium (O00-O9A)
- congenital malformations, deformations and chromosomal abnormalities (Q00-Q99)
- endocrine, nutritional and metabolic diseases (E00-E88)
- human immunodeficiency virus [HIV] disease (B20)
- injury, poisoning and certain other consequences of external causes (S00-T88)
- neoplasms (C00-D49)
- symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified (R00-R94)
D80-D89 · Certain disorders involving the immune mechanism (D80-D89)
Includes3
- defects in the complement system
- immunodeficiency disorders, except human immunodeficiency virus [HIV] disease
- sarcoidosis
Excludes 12
Excludes 21
human immunodeficiency virus [HIV] disease (B20)
D89 · Other disorders involving the immune mechanism, not elsewhere classified
Excludes 12
Excludes 21
transplant failure and rejection (T86.-)
D89.4 · Mast cell activation syndrome and related disorders
Excludes 111
- aggressive systemic mastocytosis (C96.21)
- congenital cutaneous mastocytosis (Q82.2)
- (non-congenital) cutaneous mastocytosis (D47.01)
- (indolent) systemic mastocytosis (D47.02)
- malignant mast cell neoplasm (C96.2-)
- malignant mastocytoma (C96.29)
- mast cell leukemia (C94.3-)
- mast cell sarcoma (C96.22)
- mastocytoma NOS (D47.09)
- other mast cell neoplasms of uncertain behavior (D47.09)
- systemic mastocytosis associated with a clonal hematologic non-mast cell lineage disease (SM-AHNMD) (D47.02)
Referencias del índice oficial
Referencias del índice oficial (1)
Activation (1)
- Activation › mast cell(disorder) (syndrome) › secondaryÍndice de enfermedades
Historial oficial de conversión
Historical assignments from the CDC conversion table support data retrieval. They do not authorize substituting a previous code for the current code.
Asignación anterior: D89.89
Historial
Historial del código
Último cambio registrado · FY2027
Vigente desde
- Cambios en instrucciones heredadas
Secondary mast cell activation
Código de diagnóstico facturable
CDC/NCHS · FY2027Todas las ediciones (18)
| Todas las ediciones | Vigente desde | Historial del código |
|---|---|---|
| FY2017 | 2016-10-01 | Añadido |
| FY2018 | 2017-10-01 | Cambios en instrucciones heredadas |
| FY2019 | 2018-10-01 | Sin cambios tabulares |
| FY2020 | 2019-10-01 | Sin cambios tabulares |
| FY2020 · April | 2020-04-01 | Sin cambios tabulares |
| FY2021 | 2020-10-01 | Sin cambios tabulares |
| FY2021 · 01-01 | 2021-01-01 | Sin cambios tabulares |
| FY2022 | 2021-10-01 | Sin cambios tabulares |
| FY2022 · 04-01 | 2022-04-01 | Sin cambios tabulares |
| FY2023 | 2022-10-01 | Sin cambios tabulares |
| FY2023 · 04-01 | 2023-04-01 | Sin cambios tabulares |
| FY2024 | 2023-10-01 | Sin cambios tabulares |
| FY2024 · 04-01 | 2024-04-01 | Sin cambios tabulares |
| FY2025 | 2024-10-01 | Sin cambios tabulares |
| FY2025 · 04-01 | 2025-04-01 | Sin cambios tabulares |
| FY2026 | 2025-10-01 | Cambios en instrucciones heredadas |
| FY2026 · April | 2026-04-01 | Sin cambios tabulares |
| FY2027 | 2026-10-01 | Cambios en instrucciones heredadas |
Correspondencias históricas ICD-9 · 2018
Solo correspondencia histórica; no sustituye códigos automáticamente.
- 279.8 · Aproximada
Esta entrada es un código completo en la edición seleccionada. La comprobación del catálogo no establece la pertinencia clínica ni garantiza el reembolso.